A method and system of reducing the likelihood of a Porphyrmonas gingivalis infection in a human being includes the use of an anti-biofilm agent, compounds that facilitate the growth of desired bacteria beneficial to a person's health, and compositions that reduce the growth of Porphyrmonas gingivalis bacteria, thereby reducing the virulence factor gingipain. In other embodiments, the likelihood that a subject will suffer from neurodegenerative diseases, such as Alzheimer's Disease, is reduced by administering, via local gingival application to a subject that has been diagnosed with periodontitis, an effective amount of a composition to reduce Porphyrmonas gingivalis bacteria residing on the subgingival tooth area of the subject. Methods involve the targeting of the microbiome of an individual to promote health and to treat inflammatory diseases, including specifically neurodegenerative diseases, by the modification of an individual's oral microbiome and effective management of oral health care.

A tableted chewing gum composition for oral administration of cannabinoids includes a plurality of particles, including a first population of particles having water-insoluble gum base and a second population of particles having water-soluble chewing gum ingredients. The composition constitutes at least two layers, where a first layer of the composition has water-insoluble gum base and a second layer of the composition, which is cohered to and adjacent to the first layer, has water-soluble chewing gum ingredients. The second layer is free of water-insoluble gum base, and the composition includes one or more cannabinoids.

An oral product includes a body that is wholly receivable in an oral cavity. The body includes a polymer matrix and one or more flavorants and/or active ingredients embedded in the polymer matrix. The polymer matrix can include a copolymer of ethylene and one or more vinyl monomers or zein. For example, the polymer can be ethylene-vinyl acetate copolymer and/or ethylene-vinyl alcohol copolymer. In some cases, the oral product can include tobacco and/or nicotine.

Pharmaceutical preparations are proposed, comprising bitter-masking acting substances for reducing and/or inhibiting gastric acid secretion induced by food constituents.

An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.

The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum being formulated as an extruded chewing gum including water-soluble chewing gum ingredients mixed into water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the one or more elastomer plasticizers includes one or more polyvinyl acetate elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the chewing gum has one or more cannabinoids.

The present disclosure relates to a cannabis-infused product, comprising an emulsion containing a cannabinoid profile including one or more cannabinoid, wherein the emulsion is a nanoemulsion. The disclosure also relates to methods of manufacture and of using same.

The present disclosure relates to a Cannabis-infused product comprising a cannabinoid profile including one or more cannabinoid, a first composition for controlling onset of the cannabinoid profile and a second composition for controlling offset of the cannabinoid profile in a subject having used the Cannabis-infused product, wherein the second composition has a delayed onset compared to that one of the first composition. The present disclosure also relates to methods of manufacture and of using same.

A new dissolving chewing gum product and methods to make the new chewing gum are described. A first method includes: creating a base for the dissolving chewing gum by heating, cooking, and mixing a liquid, a chew/texture component, and a texture maintenance component; adding additional components to the base; cooling the base to incorporate sensitive components; and forming individual pieces from the base. A second method occurs without a cooking step and includes: creating a base for the dissolving chewing gum by mixing a chew/texture component/texture maintenance component, adding additional components to the base, forming individual pieces of the dissolving chewing gum from the base, covering the individual pieces of the dissolving chewing gum with a coating, and adding a polish and/or a wax to the individual pieces of the dissolving chewing gum.

Oral formulations include a polysaccharide, such as, chitosan and an anthocyanin-rich extract from dark berries. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate chitosan and berry extract powder for protecting the oral cavity from the bacteria that cause gingivitis and periodontitis.